<DOC>
	<DOCNO>NCT02222740</DOCNO>
	<brief_summary>Assess safety , tolerability pharmacokinetics multiple dos 10 , 20 , 30 , 40 mg Hydrocodone Bitartrate Extended Release ( HC-ER ) capsule take food steady state , subject chronic , moderate severe osteoarthritis ( OA ) pain .</brief_summary>
	<brief_title>A Safety , Tolerability Pharmacokinetic Dose Escalation Study HC-ER Patients With Osteoarthritis Pain</brief_title>
	<detailed_description>Safety parameter assess included adverse event , physical examination , vital sign , 12-lead electrocardiogram ( ECGs ) , clinical laboratory test overall Arthritis Pain Intensity opioid side effect</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Joint Diseases</mesh_term>
	<mesh_term>Hydrocodone</mesh_term>
	<criteria>Subjects 18 year old Subjects osteoarthritis ( OA ) define : Presence typical hip and/or knee joint symptom . Involvement least 1 hip knee joint warrant treatment NonSteroidal AntiInflammatory Drugs ( NSAIDs ) , include cyclooxygenase2 [ COX2 ] inhibitor and/or acetaminophen ( APAP ) last 3 month . Radiographic evidence within last 6 month OA index joint , Grade II IV severity , illustrate Atlas Standard Radiographs . Subjects otherwise generally good health , determine investigator , basis medical history , physical examination , electrocardiogram ( ECG ) , screen laboratory result . Female subject either physically incapable childbearing practice acceptable method birth control negative pregnancy test result demonstrate dosing . Subjects experience suboptimal response APAP NSAID therapy ( include COX2 inhibitor ) . Subjects use opioids OA pain need ( PRN ) occasional basis . Subjects willing able discontinue modify current medication use management OA pain per protocol . Subjects steady , transient , pain categorical pain rating moderate severe scale none , mild , moderate , severe . Subjects weigh &gt; = to100 lb . If subject take inducer inhibitor cytochrome P450 [ CYP450j ) , discontinue appropriate washout period ( 5 halflives ) occur entry study . Subjects able take oral medication willing comply protocol . Subjects agree abstain alcohol consumption duration study . Subjects able read , understand , voluntarily sign IRB approve consent document performance studyspecific procedure . Subjects clinically significant condition would , investigator 's opinion , preclude study participation . Subjects clinically significant form disease index joint ( study joint ) diagnose inflammatory arthritis , gout , pseudogout , Paget 's disease , chronic pain syndrome , investigator 's opinion , might interfere assessment pain symptom OA . Subjects know allergy previous , significant reaction opioids . Subjects laboratory abnormality screening consider clinically significant investigator , , opinion investigator , would contraindicate study participation . Subjects know positive test result human immunodeficiency virus ( HIV ) , hepatitis B antigen , hepatitis C antibody . Subjects history chronic , schedule opioid use OA . Subjects sign symptom opioid withdrawal . Subjects history substance alcohol abuse within 2 year study entry . Subjects test positively urine screen drug abuse . Subjects receive steroid therapy ( e.g. , oral , intramuscular , intravenous , soft tissue ) within 1 month study entry . Subjects condition would contraindicate use opioid analgesia . Subjects participate study investigational drug device , donate blood , within 30 day study entry . Subjects use medication investigator felt would interact unfavorably study medication ( e.g. , potentiation sedation tricyclic antidepressant ) . Subjects use opioid analgesic 3 day 30 day screen . Subjects history seizure . Subjects consider investigator unsuitable reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>